search
Back to results

Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases (CCRe-IV)

Primary Purpose

Colonic Cancer, Unresectable Metastasis Originating in Colonic Cancer

Status
Terminated
Phase
Phase 4
Locations
Spain
Study Type
Interventional
Intervention
Colonic resection
Chemotherapy- scheme
Sponsored by
Hospital Universitari de Bellvitge
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Colonic Cancer focused on measuring Colonic cancer, Metastasis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • colorectal cancer above to 12 cm from the anal verge
  • unresectable synchronous metastases
  • no contraindications for chemotherapy
  • absence of peritoneal carcinomatosis, central nervous system o bone metastasis.
  • performance status ECOG ≤ 2 (Eastern Cooperative Oncology Group)
  • uncontrolled concomitant medical conditions that may compromise to chemotherapy
  • significant symptomatic cardiac disease
  • not pregnancy or breastfeeding

Exclusion Criteria:

  • Cases of rectal tumours below 12cm from anal verge, or locally advanced tumours invading blood vessels, nerves or bone.
  • Multiple bone metastasis or central nervous system metastasis
  • Other neoplastic disease in the 5 previous years, except squamous or basal cell skin carcinoma or cervical "in situ" carcinoma
  • Significant heart disease (chronic congestive heart failure, symptomatic coronary disease) or myocardial infarction in the previous 6 months
  • Peripheral neuropathy
  • Patients who do not give informed consent

Sites / Locations

  • Hospital Universitario Araba
  • Hospital Universitari Germans Trias i Pujol
  • Hospital Universitari de Bellvitge
  • Corporació Sanitària Parc Taulí
  • Hospital Moisès Broggi
  • Complejo Hospitalario La Mancha Centro
  • Complejo Hospitalario de Navarra
  • Complejo Hospitalario Universitario de Vigo
  • Complejo Hospitalario Torrecárdenas
  • Hospital de la Santa Creu i Sant Pau
  • Hospital del Mar
  • Hospital Univesitari Vall d'Hebron
  • Hospital Universitario Donostia
  • Hospital Universitari de Girona DrJosep Trueta
  • Hospital Univerisitario La Paz
  • Hospital Clínico Universitario Virgen de la Arrixaca
  • Complejo Hospitalario Universitario de Orense
  • Hospital Universitario Virgen del Rocío
  • Hospital Clínico Universitario de Valencia
  • Hospital General de Valencia
  • Hospital Universitari i Politècnic la Fe
  • Hospital Clínico Univeristario "Lozano Blesa"

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

colonic resection

Chemotherapy

Arm Description

Arm A (experimental): surgery (complete tumoral resection; R0) followed by chemotherapy, regimen according to each center.

Arm B (control): chemotherapy alone, regimen according to each center

Outcomes

Primary Outcome Measures

Assess the impact of overall survival in patients with unresectable metastatic colorectal cancer treated with chemotherapy alone vs surgery followed by chemotherapy.
The percentage of patients who are still alive for follow-up at 2 years after randomization.

Secondary Outcome Measures

Postoperative morbidity and mortality.
Postoperative complications were classified according to the Dindo-Clavien classification. Mortality within 30 days after surgery
Complications in patients treated with systemic chemotherapy
The toxicity will be evaluated and documented according to the CTCAE version 4.0.
Questionnaire Quality of life CR29
Specific questionnaire for colon cancer
Study of possible survival factors
Identify factors that may influence patient survival before applying any treatment (demographics, clinicals and analitycal factors, tumor characteristics; ...)

Full Information

First Posted
November 28, 2013
Last Updated
March 12, 2021
Sponsor
Hospital Universitari de Bellvitge
Collaborators
Instituto de Salud Carlos III
search

1. Study Identification

Unique Protocol Identification Number
NCT02015923
Brief Title
Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases
Acronym
CCRe-IV
Official Title
Multicenter Randomized Study in Patients With Colorectal Cancer With Unresectable Metastases. Impact of Resection vs no Resection of the Primary Tumour as a Survival Factor
Study Type
Interventional

2. Study Status

Record Verification Date
March 2021
Overall Recruitment Status
Terminated
Why Stopped
Difficulties surrounding recruiting patients
Study Start Date
December 2013 (undefined)
Primary Completion Date
June 2019 (Actual)
Study Completion Date
February 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hospital Universitari de Bellvitge
Collaborators
Instituto de Salud Carlos III

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Main outcome: Assess the impact of cancer-related survival at 2 years in patients with unresectable metastatic colorectal cancer treated with chemotherapy alone versus surgery followed by chemotherapy. To assess overall survival. To evaluate postoperative morbidity and mortality in patients treated with resection of the primary tumor. Assess complications and meed for surgery in patients treated with systemic chemotherapy only during the course of the disease. Identify and describe the complications related to chemotherapy and toxicity in the short and medium term systemic treatment. Assessing the quality of life questionnaire QLQ-C30 and QLQ-CR29. To study prognostic survival factors. Method: multicenter randomized clinical trail (22 hospitals). Two parallel group in which to evaluate two therapeutic strategies for colorectal cancer metastasis unresectable stage IV: chemotherapy alone versus primary tumor resection plus chemotherapy. Subjects: patients with unresectable nonmetastatic colorectal cancer. Hypothesis:Surgical resection of the primary tumor in stage IV colorectal patients with unresectable synchronous metastases increases by 14% overall survival compared to patients receiving systemic treatment with chemotherapy without resection of the primary tumor (survival of 34% vs 20%).
Detailed Description
Intervention: Arm B (control): chemotherapy alone, regimen according to each center. Arm A (experimental): surgery (complete tumoral resection; R0) followed by chemotherapy, regimen according to each center. Statistical Analysis: A power analysis showed that to assure a significance level of 0,05 and a beta error 0.20. 168 patients are necessary in each arm. It has been estimated a loss rate of up to 10%. Differences between groups will be analyzed by t, U, X2, exact test and survival will be assessed according to Kaplan and Meier method. Evaluation of safety of the trial will be made in the middle of the study statistically

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colonic Cancer, Unresectable Metastasis Originating in Colonic Cancer
Keywords
Colonic cancer, Metastasis

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
107 (Actual)

8. Arms, Groups, and Interventions

Arm Title
colonic resection
Arm Type
Experimental
Arm Description
Arm A (experimental): surgery (complete tumoral resection; R0) followed by chemotherapy, regimen according to each center.
Arm Title
Chemotherapy
Arm Type
Active Comparator
Arm Description
Arm B (control): chemotherapy alone, regimen according to each center
Intervention Type
Procedure
Intervention Name(s)
Colonic resection
Intervention Description
Colonic cancer resection, R0 No surgical intervention on metastasis
Intervention Type
Drug
Intervention Name(s)
Chemotherapy- scheme
Other Intervention Name(s)
FOLFOX-4, FOLFOX-6, FOLFIRI, FOLFOXIRI, CAPOX, CETUXIMAX / BEVACIZUMAB/PANITUMUMAB
Intervention Description
Chemotherapy, specified in each center with or without biological drugs
Primary Outcome Measure Information:
Title
Assess the impact of overall survival in patients with unresectable metastatic colorectal cancer treated with chemotherapy alone vs surgery followed by chemotherapy.
Description
The percentage of patients who are still alive for follow-up at 2 years after randomization.
Time Frame
up to 2 years
Secondary Outcome Measure Information:
Title
Postoperative morbidity and mortality.
Description
Postoperative complications were classified according to the Dindo-Clavien classification. Mortality within 30 days after surgery
Time Frame
30 days postoperatively
Title
Complications in patients treated with systemic chemotherapy
Description
The toxicity will be evaluated and documented according to the CTCAE version 4.0.
Time Frame
up to 2 years
Title
Questionnaire Quality of life CR29
Description
Specific questionnaire for colon cancer
Time Frame
up to 2 years
Title
Study of possible survival factors
Description
Identify factors that may influence patient survival before applying any treatment (demographics, clinicals and analitycal factors, tumor characteristics; ...)
Time Frame
up to 2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: colorectal cancer above to 12 cm from the anal verge unresectable synchronous metastases no contraindications for chemotherapy absence of peritoneal carcinomatosis, central nervous system o bone metastasis. performance status ECOG ≤ 2 (Eastern Cooperative Oncology Group) uncontrolled concomitant medical conditions that may compromise to chemotherapy significant symptomatic cardiac disease not pregnancy or breastfeeding Exclusion Criteria: Cases of rectal tumours below 12cm from anal verge, or locally advanced tumours invading blood vessels, nerves or bone. Multiple bone metastasis or central nervous system metastasis Other neoplastic disease in the 5 previous years, except squamous or basal cell skin carcinoma or cervical "in situ" carcinoma Significant heart disease (chronic congestive heart failure, symptomatic coronary disease) or myocardial infarction in the previous 6 months Peripheral neuropathy Patients who do not give informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sebastiano Biondo, Sponsor
Organizational Affiliation
Hospital Universitari de Bellvitge
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Javier Vaqué
Organizational Affiliation
Hospital Universitario La Fe
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Juan García Armengol
Organizational Affiliation
Hospital General Universitario de Valencia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Laura Mora
Organizational Affiliation
Corporacion Parc Tauli
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ignasi Camps Ausàs
Organizational Affiliation
Hospital Universitari Gemans Tiras i Pujol
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Miguel Pera Román
Organizational Affiliation
Hospital Univesitari del Mar
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Eduardo Targarona Soler
Organizational Affiliation
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Lorenzo Viso Pons
Organizational Affiliation
Hospital de Sant Joan Despí Moisès Broggi
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
José Manuel Ramírez Rodríguez
Organizational Affiliation
Hospital Clínico Univeristario "Lozano Blesa"
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
David Julià Bergkvist
Organizational Affiliation
Hospital Universitari de Girona DrJosep Trueta
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Teresa García Martínez
Organizational Affiliation
Complejo Hospitalario Universitario de Vigo
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mario Álvarez Gallego
Organizational Affiliation
Hospital Univerisitario La Paz
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
José María Enríquez Navascués
Organizational Affiliation
Hospital Universitario Donostia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Fernando de la Portilla de Juan
Organizational Affiliation
Hospitales Universitarios Virgen del Rocío
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Miguel Angel Ciga
Organizational Affiliation
Complejo Hospitalario de Navarra
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Eloy Espín Basany
Organizational Affiliation
hospital Universitari de la Vall D'Hebron
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Manuel Ferrer Márquez
Organizational Affiliation
Complejo Hospitalario Torrecárdenas
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jesús Abrisqueta Carrión
Organizational Affiliation
Hospital Clínico Universitario Virgen de la Arrixaca
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
José Errasti Alustiza
Organizational Affiliation
Hospital Universitario Araba
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Alberto Parajó Calvo
Organizational Affiliation
Complejo Hospitalario Universitario de Orense
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Carlos Moreno Sanz
Organizational Affiliation
Complejo Hospitalario La Mancha Centro
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Alejando Espí Macías
Organizational Affiliation
Hospital Clínico Universitario de Valencia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ricard Frago Montanuy
Organizational Affiliation
Hospital Universitari de Bellvitge
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Universitario Araba
City
Vitoria/Gasteiz
State/Province
Araba
Country
Spain
Facility Name
Hospital Universitari Germans Trias i Pujol
City
Badalona
State/Province
Barcelona
Country
Spain
Facility Name
Hospital Universitari de Bellvitge
City
L'Hospitalet de Llobregat
State/Province
Barcelona
ZIP/Postal Code
08709
Country
Spain
Facility Name
Corporació Sanitària Parc Taulí
City
Sabadell
State/Province
Barcelona
Country
Spain
Facility Name
Hospital Moisès Broggi
City
Sant Joan Despí
State/Province
Barcelona
Country
Spain
Facility Name
Complejo Hospitalario La Mancha Centro
City
Alcazar de San Juan
State/Province
Ciudad Real
Country
Spain
Facility Name
Complejo Hospitalario de Navarra
City
Pamplona
State/Province
Navarra
Country
Spain
Facility Name
Complejo Hospitalario Universitario de Vigo
City
Vigo
State/Province
Pontevedra
Country
Spain
Facility Name
Complejo Hospitalario Torrecárdenas
City
Almería
Country
Spain
Facility Name
Hospital de la Santa Creu i Sant Pau
City
Barcelona
Country
Spain
Facility Name
Hospital del Mar
City
Barcelona
Country
Spain
Facility Name
Hospital Univesitari Vall d'Hebron
City
Barcelona
Country
Spain
Facility Name
Hospital Universitario Donostia
City
Donostia
Country
Spain
Facility Name
Hospital Universitari de Girona DrJosep Trueta
City
Girona
Country
Spain
Facility Name
Hospital Univerisitario La Paz
City
Madrid
Country
Spain
Facility Name
Hospital Clínico Universitario Virgen de la Arrixaca
City
Murcia
Country
Spain
Facility Name
Complejo Hospitalario Universitario de Orense
City
Ourense
Country
Spain
Facility Name
Hospital Universitario Virgen del Rocío
City
Sevilla
Country
Spain
Facility Name
Hospital Clínico Universitario de Valencia
City
Valencia
Country
Spain
Facility Name
Hospital General de Valencia
City
Valencia
Country
Spain
Facility Name
Hospital Universitari i Politècnic la Fe
City
Valencia
Country
Spain
Facility Name
Hospital Clínico Univeristario "Lozano Blesa"
City
Zaragoza
Country
Spain

12. IPD Sharing Statement

Citations:
PubMed Identifier
28497402
Citation
Biondo S, Frago R, Kreisler E, Espin-Basany E; Spanish CR4 Group. Impact of resection versus no resection of the primary tumor on survival in patients with colorectal cancer and synchronous unresectable metastases: protocol for a randomized multicenter study (CR4). Int J Colorectal Dis. 2017 Jul;32(7):1085-1090. doi: 10.1007/s00384-017-2827-3. Epub 2017 May 11.
Results Reference
derived

Learn more about this trial

Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases

We'll reach out to this number within 24 hrs